指南与共识肝病

基于Fibrosis-4与FibroScan的六项国际指南对2型糖尿病合并代谢功能障碍相关脂肪性肝病风险分层的效果

Effectiveness of Six International Guidelines Using Fibrosis-4 and FibroScan for Risk Stratification of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes.
指南 / 共识 · Clin Gastroenterol Hepatol · 2025-05-08

研究前瞻性筛查1572例2型糖尿病门诊患者,其中163例接受肝活检,比较六项国际指南路径(EASL 2021、EASL 2024、AASLD、AGA、AACE、ADA)使用Fibrosis-4序贯振动控制瞬时弹性成像(VCTE)进行MASLD纤维化风险分层的效果。六项路径需肝病科转诊比例相似(12%),以VCTE作为一线检查时转诊比例更高(19%)且F3F4假阴性率低(3%)。

要点

  • 六项指南路径在2型糖尿病门诊患者中需肝病科转诊比例相似,均为12%。
  • 以VCTE作为一线检查时肝病科转诊比例更高(19%),F3F4假阴性率低(3%)。
  • F3F4路径(EASL、AGA、AASLD)假阳性率(36%-39%)高于假阴性率(15%-18%)。

核心结论

  • 六项指南路径在糖尿病门诊2型糖尿病患者中需肝病科转诊比例相似(12%),以VCTE作为一线检查时转诊比例更高(19%)且F3F4假阴性率低(3%)。

研究设计与样本

  • 前瞻性筛查1572例2型糖尿病门诊患者(60%男性;中位年龄61岁),其中163例接受肝活检。
  • 应用EASL 2021、EASL 2024、AASLD、AGA、AACE和ADA六项路径,使用Fibrosis-4序贯振动控制瞬时弹性成像(VCTE)。

主要发现

  • 在1572例患者中,6项路径表现相似,识别需肝病科转诊的患者比例为12%。
  • 在163例患者中,F3F4(EASL、AGA和AASLD)的假阳性率(36%-39%)高于假阴性率(15%-18%)。
  • F2F4(AACE和ADA)的假阴性率为17%,假阳性率为44%。
  • 以VCTE作为一线检查时,需肝病科转诊比例更高(19%),F3F4假阴性率低(3%)。

关键数值与推荐

  • EASL、AGA和AASLD路径以F3F4为结局,AACE和ADA路径以F2F4为结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Screening of patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), who are at high risk for significant (F2F4) or advanced fibrosis (F3F4), is an unmet need. Recently, several pathways have been proposed to screen patients at risk for MASLD and fibrosis. We aimed to compare their performance in a large cohort of outpatients with T2D. METHODS: A total of 1572 participants with T2D (60% male; median age, 61 years) attending a diabetes clinic were prospectively screened for MASLD (steatosis and/or elevated alanine aminotransferase) of whom 163 underwent liver biopsy. The European Association for the Study of the Liver (EASL) 2021, 2024, American Association for the Study of Liver Diseases (AASLD), American Gastroenterological Association (AGA), American Association of Clinical Endocrinology (AACE), and American Diabetes Association (ADA) pathways were applied using Fibrosis-4 followed by vibration-controlled transient elastography (VCTE). Outcomes were the percent requiring hepatology referral and the false negative and positive rates in patients according to liver biopsy (F3F4 for EASL, AGA and AASLD and F2F4 for AACE and ADA). RESULTS: In the 1572 patients, the 6 pathways performed similarly, identifying 12% of patients requiring hepatology referral. In the 163 patients, the false positive rates (36%-39%) were higher than the false negative rates (15%-18%) for F3F4 (EASL, AGA, and AASLD), whereas the opposite was true for F2F4 (AACE and ADA) (17% and 44%, respectively). Using VCTE as the first line, resulted in a higher percentage of hepatology referrals (19%) and a low false negative rate (3%) for F3F4. CONCLUSIONS: The percentage of patients with T2D in diabetes clinics requiring referral to hepatology (12%) was similar across the 6 pathways, but higher (19%) when VCTE was used as the first line, with a low false negative rate (3%) for advanced fibrosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Vidal-Trécan T, Julla JB, El Khoury T, et al. Effectiveness of Six International Guidelines Using Fibrosis-4 and FibroScan for Risk Stratification of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes. Clin Gastroenterol Hepatol. 2025. PMID: 40348110. doi:10.1016/j.cgh.2025.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。